The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
Open accessAbstract
Importance: Patients with cancer undergoing treatment are at high risk of COVID-19 following SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to messenger RNA SARS-CoV-2 vaccines is unclear. Objective: To evaluate rates of antispike (anti-S) antibody response to a BNT162b2 vaccine in patients with cancer who are undergoing systemic treatment vs healthy controls. Design, Setting, and Participants: This prospective cohort study included 102 adult patients with solid tumors undergoing active intravenous anticancer treatment and 78 controls who received the second dose of the BNT162b2 vaccine at least 12 days before enrollment. The controls were taken from a convenience sample of the patients' family/caregivers who accompanied them to treatment. The study was conducted between February 22, 2021, and March 15, 2021 at Davidoff Cancer Center at Beilinson Hospital (Petah Tikva, Israel). Interventions: Blood samples were drawn from the study participants. Serum samples were analyzed and the titers of the IgG antibodies against SARS-CoV-2 spike receptor-binding domain were determined using a commercially available immunoassay. Seropositivity was defined as 50 or greater AU/mL. Main Outcomes and Measures: The primary outcome was the rate of seropositivity. Secondary outcomes included comparisons of IgG titers and identifying factors that were associated with seropositivity using univariate/multivariable analyses. Results: The analysis included 180 participants, which comprised 102 patients with cancer (median [interquartile range (IQR)] age, 66 [56-72] years; 58 men [57%]) and 78 healthy controls (median [IQR] age, 62 [49-70] years; 25 men [32%]). The most common tumor type was gastrointestinal (29 [28%]). In the patient group, 92 (90%) were seropositive for SARS-CoV 2 antispike IgG antibodies after the second vaccine dose, whereas in the control group, all were seropositive. The median IgG titer in the patients with cancer was significantly lower than that in the controls (1931 [IQR, 509-4386] AU/mL vs 7160 [IQR, 3129-11 241] AU/mL; P < .001). In a multivariable analysis, the only variable that was significantly associated with lower IgG titers was treatment with chemotherapy plus immunotherapy (β, -3.5; 95% CI, -5.6 to -1.5). Conclusions and Relevance: In this cohort study of patients with cancer who were receiving active systemic therapy, 90% of patients exhibited adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research into the clinical relevance of lower titers and their durability is required. Nonetheless, the data support vaccinating patients with cancer as a high priority, even during therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Immunotherapy + biological therapy 5 521 (505-2962) [11-3988]”
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Evidence for antibody as a protective correlate for COVID-19 vaccines
Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.063 · Cited by 870
Evidence for antibody as a protective correlate for COVID-19 vaccines
Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · doi:10.1101/2021.03.17.20200246 · Cited by 870
The untold toll—the pandemic's effects on patients without covid-19
Rosenbaum, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmms2009984 · Cited by 698
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Saini, K. S., Tagliamento, M., Lambertini, M., McNally, R., Romano, M., Leone, M., Curigliano, G., & de Azambuja, E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.011 · Cited by 331
Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study
Jazieh, A. R., Akbulut, H., Curigliano, G., Rogado, A., Alsharm, A. A., Razis, E. D., Mula-Hussain, L., Errihani, H., Khattak, A., De Guzman, R. B., et al. (2020) · JCO Global Oncology · doi:10.1200/go.20.00351 · Cited by 277
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R., Meyer, W. A., Kaufman, H. W., Anderson, S., Cohen, O., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.0366 · Cited by 272
Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care
Jones, D., Neal, R. D., Duffy, S. R. G., Scott, S. E., Whitaker, K. L., & Brain, K. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30242-4 · Cited by 268
Impaired Antibody Response to Pneumococcal Vaccine after Treatment for Hodgkin's Disease
Siber, G. R., Weitzman, S. A., Aisenberg, A. C., Weinstein, H. J., & Schiffman, G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197808312990903 · Cited by 210
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Ribas, A., Sengupta, R., Locke, T., Zaidi, S. K., Campbell, K. M., Carethers, J. M., Jaffee, E. M., Wherry, E. J., Soria, J.-C., & D'Souza, G. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1817 · Cited by 198
Desai, A. P., Gupta, R., Advani, S., Ouellette, L., Kuderer, N. M., Lyman, G. H., & Li, A. (2020) · Cancer · doi:10.1002/cncr.33386 · Cited by 136
Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories
Harritshøj, L. H., Gybel‐Brask, M., Afzal, S., Kamstrup, P. R., Jørgensen, C. S., Thomsen, M. K., Hilsted, L. M., Friis-Hansen, L. J., Szecsi, P. B., Pedersen, L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02596-20 · Cited by 133
Nordøy, T., Aaberge, I. S., Husebekk, A., Samdal, H. H., Steinert, S., Melby, H., & Kolstad, A. (2002) · Medical Oncology · doi:10.1385/mo:19:2:71 · Cited by 107
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer
Rugge, M., Zorzi, M., & Guzzinati, S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0104-9 · Cited by 103
Jin, P., Li, J., Pan, H., Wu, Y., & Zhu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00481-y · Cited by 83
Seroconversion after influenza vaccination in patients with lung cancer
Anderson, H., Petrie, K. J., Berrisford, C., Charlett, A., Thatcher, N., & Zambon, M. C. F. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690342 · Cited by 80
Response to influenza virus vaccination during chemotherapy in patients with breast cancer
Meerveld-Eggink, A., de Weerdt, O., van der Velden, A. M. T., Los, M., van der Velden, A. W. G., Stouthard, J. M., Nijziel, M. R., Westerman, M., Beeker, A., van Beek, R., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq728 · Cited by 59
Humoral immune response after vaccination against influenza in patients with breast cancer
Brydak, L. B., Guzy, J., Starzyk, J., Machała, M. K., & Góźdź, S. S. (2001) · Supportive Care in Cancer · doi:10.1007/s005200000186 · Cited by 56
Influenza Vaccination in Cancer Patients Undergoing Systemic Therapy
Shehata, M., & Karim, N. A. (2014) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s13774 · Cited by 41
Influenza vaccination in patients with breast cancer: a case-series analysis.
Vilar‐Compte, D., Cornejo, P., Valle-Salinas, A., Roldán–Marín, R., Iguala, M., Cervantes, Y., & López, I. (2006) · PubMed · Cited by 22
Cited by
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee, A. R. Y. B., Wong, S. Y., Chai, L. Y. A., Lee, S. C., Lee, M. X., Muthiah, M. D., Tay, S. H., Teo, C. B., Tan, B. K. J., Chan, Y. H., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068632 · Cited by 498
Metadata
- Authors
- Massarweh, A., Eliakim-Raz, N., Stemmer, A., Levy-Barda, A., Yust-Katz, S., Zer, A., Benouaich-Amiel, A., Ben-Zvi, H., Moskovits, N., Brenner, B., Bishara, J., Yahav, D., Tadmor, B., Zaks, T., & Stemmer, S. M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-08-01
- Volume
- 7
- Issue
- 8
- Pages
- 1133
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3164768289
- Cited by
- 265
- References
- 29
- FWCI
- 18.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.